Latest Articles

Publication Date
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? - Oncology Nursing News

Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? Oncology Nursing News

Published: Jan. 14, 2026, 7:32 p.m.
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks

Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity TipRanks

Published: Jan. 14, 2026, 4:33 p.m.
Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma - springermedicine.com

Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma springermedicine.com

Published: Jan. 14, 2026, 6:02 a.m.
More people are living 5 years after cancer diagnosis, new ACS data shows - ABC7 New York

More people are living 5 years after cancer diagnosis, new ACS data shows ABC7 New York

Published: Jan. 13, 2026, 6:07 p.m.
More people are living 5 years after cancer diagnosis, new ACS data shows - ABC7 Los Angeles

More people are living 5 years after cancer diagnosis, new ACS data shows ABC7 Los Angeles

Published: Jan. 13, 2026, 5:02 p.m.
More people are living 5 years after cancer diagnosis, new ACS data shows - ABC30 Fresno

More people are living 5 years after cancer diagnosis, new ACS data shows ABC30 Fresno

Published: Jan. 13, 2026, 5:02 p.m.
ASCO 2025: key highlights in endometrial cancer - springermedicine.com

ASCO 2025: key highlights in endometrial cancer springermedicine.com

Published: Jan. 13, 2026, 5:23 a.m.
Therapeutic potential of epigallocatechin gallate in gynecologic cancer, endometriosis, polycystic ovary syndrome: a mechanistic and translational perspective.

Tea, among the most widely consumed beverages worldwide, is rich in polyphenolic compounds known as catechins, particularly epigallocatechin gallate (EGCG). This review aims to synthesize recent findings and ongoing controversies …

Published: Jan. 13, 2026, midnight
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer - The ASCO Post

Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer The ASCO Post

Published: Jan. 12, 2026, 6:10 p.m.
En Bloc Hysterectomy with segmental bowel resection by NOSE-procedure: Surgical Management of Ovarian Cancer in context of Deep Infiltrating Endometriosis.

To show the safety of en bloc hysterectomy with segmental bowel resection utilizing the NOSE-technique in the management of ovarian cancer and deep infiltrating endometriosis (DIE).

Published: Jan. 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!